Truist Slashes PT on Vericel Corporation (VCEL) to $45 From $50

Vericel Corporation (NASDAQ:VCEL) is 1 of the champion small headdress stocks to bargain with immense upside potential. Truist expert Richard Newitter slashed the terms people connected Vericel Corporation (NASDAQ:VCEL) to $45 from $50 connected December 18, reaffirming a Buy standing connected the banal arsenic portion of a broader probe enactment previewing the coming twelvemonth for the MedTech sector. Similarly, connected December 16, Canaccord Genuity reaffirmed a Buy standing connected Vericel Corporation (NASDAQ:VCEL) and acceptable a $58 terms target.

In its fiscal Q3 2025 results, Vericel Corporation (NASDAQ:VCEL) reported that the full nett gross for the 4th roseate to $67.5 cardinal compared to $57.9 cardinal successful the anterior twelvemonth period, portion full nett merchandise gross included $55.7 cardinal of MACI (autologous cultured chondrocytes connected porcine collagen membrane) nett gross compared to $44.7 cardinal successful the anterior twelvemonth period, and $10.4 cardinal of Epicel (cultured epidermal autografts) nett gross compared to $44.7 million. It besides included $1.5 cardinal of NexoBrid (anacaulase-bcdb) nett revenue, down from  $1.1 cardinal successful fiscal Q3 2024.

Vericel Corporation (NASDAQ:VCEL) further reported that the full operating expenses for the 4th roseate to $46.1 cardinal compared to $44.1 cardinal for the aforesaid play successful 2024, with the summation chiefly attributed to the emergence successful headcount and related worker expenses, on with further costs related to the company’s caller Burlington facility, including depreciation and MACI tech transportation activities.

Vericel Corporation (NASDAQ:VCEL) has a full full-year gross guidance of $272 to $276 million, and reaffirmed its MACI full-year gross maturation successful the debased 20% range, oregon $237.5 to $239.5 million. The institution besides reaffirmed full-year profitability guidance of 74% gross borderline and adjusted EBITDA borderline of 26%.

Vericel Corporation (NASDAQ:VCEL) is progressive successful merchandise development, research, manufacturing, and organisation of patient-specific, expanded cellular therapies that assistance dainty diseases. The company’s merchandise portfolio includes Epicel and MACI. Epicel covers tegument replacement for patients with heavy dermal oregon full-thickness burns, portion the MACI portfolio is FDA-approved for the process of insubstantial engineering for compartment maturation connected scaffolds utilizing steadfast cartilage insubstantial derived from the patient’s ain knee.

While we admit the imaginable of VCEL arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.